Get the Stockscreener App
5.84
11.88%
0.62
After Hours:
5.84
Alpha Tau Medical Ltd stock is traded at $5.84, with a volume of 347.85K.
It is up +11.88% in the last 24 hours and up +50.13% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
See More
Previous Close:
$5.22
Open:
$5.31
24h Volume:
347.85K
Relative Volume:
3.07
Market Cap:
$497.94M
Revenue:
-
Net Income/Loss:
$-29.64M
P/E Ratio:
-13.58
EPS:
-0.43
Net Cash Flow:
$-39.43M
1W Performance:
+16.10%
1M Performance:
+50.13%
6M Performance:
+84.23%
1Y Performance:
+84.23%
1-Day Range:
$5.20
$5.87
1-Week Range:
$4.75
$5.87
52-Week Range:
$2.30
$5.87
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
5.84 | 445.08M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau Medical Unveils Strong Pancreatic Cancer Alpha DaRT Data Ahead of ASCO GI 2026 - TipRanks
Alpha Tau reports new positive results in two upcoming presentations - marketscreener.com
Alpha Tau Reports New Positive Results in Two Upcoming - GlobeNewswire
Alpha Tau Medical stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Advancing Alpha DaRT: Regulatory Momentum, Pipeline Expansion, and Favorable Risk–Reward Support Buy Rating on Alpha Tau Medical - TipRanks
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation - The Globe and Mail
Bond Watch: Is Alpha Tau Medical Ltd stock a buy before product launchesJuly 2025 Gainers & Long-Term Capital Growth Strategies - moha.gov.vn
Alpha Tau submits first pre-market approval module to the FDA - marketscreener.com
Alpha Tau Files First FDA PMA Module for Alpha DaRT Skin Cancer Therapy - TipRanks
Alpha Tau submits PMA module to FDA for Alpha DaRT - TipRanks
Alpha Tau Submits First Pre-Market Approval Module to the - GlobeNewswire
What drives Alpha Tau Medical Ltd stock priceSwing Trading Watchlist & High Return Capital Gains - earlytimes.in
Alpha Tau Medical (DRTSW) Stock Analysis Report | Financials & Insights - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Graphite India Limited At Decision Level — Rebound or ResistanceSupport Zone Identification & Double Digit Profit Strategies - bollywoodhelpline.com
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Up 58.8% in December - MarketBeat
Pharma News: Can Alpha Tau Medical Ltd Equity Warrant stock hit record highs again2025 Market Outlook & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
How supply chain issues affect Alpha Tau Medical Ltd. stock2025 Market Overview & AI Driven Price Predictions - Улправда
Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium - MSN
Will Alpha Tau Medical Ltd. stock attract more institutional investorsPortfolio Performance Report & Accurate Trade Setup Notifications - Улправда
Will Alpha Tau Medical Ltd. Equity Warrant stock sustain high P E ratios2025 Retail Activity & AI Based Trade Execution Alerts - Улправда
Entry Recap: How supply chain issues affect Alpha Tau Medical Ltd. stockJuly 2025 Earnings & Weekly High Potential Alerts - Улправда
Why Alpha Tau Medical Ltd. stock remains a top recommendationBuy Signal & Intraday High Probability Setup Alerts - Улправда
Will Alpha Tau Medical Ltd. stock deliver shareholder valueQuarterly Profit Review & Verified Short-Term Plans - Улправда
Earnings Miss: How rising interest rates impact Alpha Tau Medical Ltd. Equity Warrant stock2025 Sector Review & Smart Swing Trading Alerts - Улправда
Market Recap: What insider trading reveals about Alpha Tau Medical Ltd. stockJuly 2025 Drop Watch & Risk Managed Investment Signals - Улправда
Alpha Tau Medical’s innovative cancer treatment study update: A potential game-changer - MSN
Is Alpha Tau Medical Ltd. stock a buy before product launches2025 AllTime Highs & Fast Gain Swing Alerts - Bölüm Sonu Canavarı
Will Alpha Tau Medical Ltd. Equity Warrant stock outperform Nasdaq index2025 Volume Leaders & AI Powered Market Trend Analysis - Улправда
Why Alpha Tau Medical Ltd. stock is seen as undervaluedTrade Volume Report & Stock Timing and Entry Methods - Улправда
Will Alpha Tau Medical Ltd. stock benefit from infrastructure spendingQuarterly Earnings Summary & AI Optimized Trade Strategies - DonanımHaber
Will Alpha Tau Medical Ltd. stock attract ESG investorsWeekly Stock Report & Daily Volume Surge Signals - Улправда
How Alpha Tau Medical Ltd. Equity Warrant stock performs during Fed tightening cyclesWeekly Profit Recap & Long-Term Growth Portfolio Plans - DonanımHaber
Aug Levels: Will Alpha Tau Medical Ltd. stock attract more institutional investorsJuly 2025 Big Picture & Daily Profit Focused Screening - Улправда
Is Alpha Tau Medical Ltd. stock positioned for long term growthJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда
Is Alpha Tau Medical Ltd. Equity Warrant stock a top pick in earnings seasonJuly 2025 News Drivers & Weekly Sector Rotation Insights - Улправда
Is Alpha Tau Medical Ltd. stock positioned well for digital economyBond Market & Breakout Confirmation Alerts - Улправда
Buyout Rumor: Is Alpha Tau Medical Ltd. Equity Warrant stock a top pick in earnings season2025 Technical Overview & Free Real-Time Market Sentiment Alerts - Улправда
Will Alpha Tau Medical Ltd. stock outperform tech sector in 2025Market Risk Summary & Accurate Intraday Trade Tips - Улправда
Alpha Tau Expands Alpha DaRT Into Recurrent Prostate Cancer: What Investors Should Watch - TipRanks
Alpha Tau Medical to Present Corporate Update at J.P. Morgan 2026 Healthcare Conference - TipRanks
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference - The Manila Times
Alpha Tau Medical (NASDAQ: DRTS) to present at J.P. Morgan 2026 event - Stock Titan
Risk Report: Is Alpha Tau Medical Ltd. Equity Warrant stock a top pick in earnings season2025 Market Outlook & Consistent Profit Trade Alerts - Улправда
How rising interest rates impact Alpha Tau Medical Ltd. Equity Warrant stockJuly 2025 Final Week & Precise Buy Zone Identification - Улправда
What insider trading reveals about Alpha Tau Medical Ltd. stockWeekly Risk Report & Weekly Stock Breakout Alerts - Улправда
Alpha Tau Medical’s innovative prostate cancer therapy: study completion update - MSN
Alpha Tau Medical’s Innovative Cancer Treatment Study Update: A Potential Game-Changer - TipRanks
Death Cross: Will Alpha Tau Medical Ltd Equity Warrant stock maintain growth story2025 Top Gainers & Risk Controlled Stock Alerts - moha.gov.vn
Alpha Tau Medical’s Innovative Prostate Cancer Therapy: Study Completion Update - TipRanks
Alpha Tau Medical up sharply as brain cancer trial beginsGlobes - Globes - Israel Business News
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):